Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.38 |
| ▸ | GNRHR | P30968 | 7/20 | 0.37 |
| ▸ | BACE1 | P56817 | 4/20 | 0.37 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918367 | 0.92 | BACE1 (0.41) | KISS1RGNRHRBACE1BDKRB2CTNNB1 | |
| SCHEMBL30958914 | 0.92 | KISS1R (0.41) | KISS1RGNRHRBACE1BDKRB2CTNNB1 | |
| SCHEMBL30918341 | 0.92 | CTSB (0.38) | KISS1RBACE1CTNNB1CTSBCTSS | |
| SCHEMBL30918311 | 0.89 | PTPN1 (0.42) | CTSBCTSSCTSK | |
| SCHEMBL30958909 | 0.86 | BACE1 (0.39) | KISS1RBACE1CTSB | |
| SCHEMBL30918343 | 0.79 | BACE1 (0.46) | KISS1RBACE1CTSB | |
| SCHEMBL29666838 | 0.79 | TACR1 (0.34) | GNRHRBDKRB2CTSBCTSSCTSK | |
| SCHEMBL27428789 | 0.76 | TACR1 (0.36) | KISS1R | |
| SCHEMBL27429103 | 0.76 | TACR1 (0.36) | KISS1R | |
| SCHEMBL27389137 | 0.76 | TACR1 (0.36) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | KISS1R 1618/4885GNRHR 962/4885BACE1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.